UA40596C2 - Композиція вакцини та спосіб її одержання - Google Patents

Композиція вакцини та спосіб її одержання

Info

Publication number
UA40596C2
UA40596C2 UA94129182A UA94129182A UA40596C2 UA 40596 C2 UA40596 C2 UA 40596C2 UA 94129182 A UA94129182 A UA 94129182A UA 94129182 A UA94129182 A UA 94129182A UA 40596 C2 UA40596 C2 UA 40596C2
Authority
UA
Ukraine
Prior art keywords
vaccine composition
preparation
antigen
hbsag
adjuvant
Prior art date
Application number
UA94129182A
Other languages
English (en)
Russian (ru)
Inventor
Жан Петре
П'єр Хаузер
П'ер Хаузер
Original Assignee
Смітклайн Бічем Байолоджікалс С.А.
Смитклайн Бичем Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26300928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA40596(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929211081A external-priority patent/GB9211081D0/en
Priority claimed from GB929213308A external-priority patent/GB9213308D0/en
Application filed by Смітклайн Бічем Байолоджікалс С.А., Смитклайн Бичем Байолоджикалс С.А. filed Critical Смітклайн Бічем Байолоджікалс С.А.
Publication of UA40596C2 publication Critical patent/UA40596C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Даний винахід стосується нових вакцин, способів їх приготування та застосування у терапії. Композиція вакцини містить антиген і ад’ювант, причому як антиген вона містить імунологічно ефективну кількість поверхневого антигену гепатиту В і ряд (n) інших антигенів, при цьому як ад’ювант вона містить одну або більше солей алюмінію, причому n має значення 1 і більше, а ад’ювант з адсорбованим на ньому поверхневим антигеном гепатиту В являє собою фосфат алюмінію за умови, що, коли n дорівнює одиниці, то інший антиген являє собою антиген, відмінний він антигену проти гепатиту А.
UA94129182A 1992-05-23 1993-05-15 Композиція вакцини та спосіб її одержання UA40596C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929211081A GB9211081D0 (en) 1992-05-23 1992-05-23 Vaccines
GB929213308A GB9213308D0 (en) 1992-06-23 1992-06-23 Vaccine
PCT/EP1993/001276 WO1993024148A1 (en) 1992-05-23 1993-05-15 Combined vaccines comprising hepatitis b surface antigen and other antigens

Publications (1)

Publication Number Publication Date
UA40596C2 true UA40596C2 (uk) 2001-08-15

Family

ID=26300928

Family Applications (1)

Application Number Title Priority Date Filing Date
UA94129182A UA40596C2 (uk) 1992-05-23 1993-05-15 Композиція вакцини та спосіб її одержання

Country Status (30)

Country Link
US (1) US6013264A (uk)
EP (4) EP0642355B1 (uk)
JP (1) JP3626996B2 (uk)
KR (1) KR100287083B1 (uk)
CN (2) CN1313152C (uk)
AP (1) AP567A (uk)
AT (2) ATE444079T1 (uk)
AU (5) AU4315693A (uk)
CA (1) CA2136429C (uk)
CY (1) CY2614B2 (uk)
CZ (1) CZ283910B6 (uk)
DE (4) DE69334297D1 (uk)
DK (2) DK0642355T3 (uk)
ES (2) ES2334181T3 (uk)
FI (1) FI945483A7 (uk)
HU (1) HU220236B (uk)
IL (1) IL105770A (uk)
LU (2) LU91658I2 (uk)
MA (1) MA22894A1 (uk)
MX (1) MX9302982A (uk)
MY (1) MY110665A (uk)
NO (1) NO309675B1 (uk)
NZ (1) NZ253065A (uk)
PT (1) PT835663E (uk)
RU (1) RU2160120C2 (uk)
SG (1) SG48365A1 (uk)
SI (1) SI9300271A (uk)
SK (1) SK280702B6 (uk)
UA (1) UA40596C2 (uk)
WO (1) WO1993024148A1 (uk)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2465316C1 (ru) * 2011-10-05 2012-10-27 Общество с ограниченной ответственностью "ГРИТВАК" Штамм бактерий haemophilus influenzae в №326, стабильный продуцент капсульного полисахарида
RU2499046C2 (ru) * 2007-10-30 2013-11-20 Сентро Де Инхеньерия Хенетика И Биотекнолохия Полинуклеотидная последовательность, кодирующая сконструированный белок пертактин, вектор, включающий такую последовательность, и вакцинные композиции, содержащие белок пертактина или вектор

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US6696065B1 (en) 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
FR2734484B1 (fr) 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
EP1082965B1 (en) 1995-06-23 2009-06-10 GlaxoSmithKline Biologicals S.A. A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
DK0914153T3 (da) * 1996-07-02 2007-01-29 Sanofi Pasteur Ltd Multivalente DTP-poliovacciner
GB9623233D0 (en) * 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
US20010014331A1 (en) 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
CU22629A1 (es) * 1997-03-06 2000-12-22 Ct Ingenieria Genetica Biotech Formulaciones inmunopotenciadoras para uso vacunal
WO1998050071A1 (en) * 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
WO1999013906A1 (en) * 1997-09-15 1999-03-25 Pasteur Merieux Msd Multivalent vaccines
KR20010041629A (ko) * 1998-03-09 2001-05-25 장 스테판느 혼합 백신 조성물
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
US20030049268A1 (en) 1998-05-01 2003-03-13 Smithkline Beecham Biologicals S.A. Novel composition
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
RU2130778C1 (ru) * 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
RU2130779C1 (ru) * 1998-07-31 1999-05-27 Акционерное общество закрытого типа Научно-производственная компания "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка и дифтерии
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
CN101926993B (zh) 1998-10-16 2013-12-04 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
CN1053590C (zh) * 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US6974581B1 (en) * 1998-12-15 2005-12-13 Aventis Pasteur Limited Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease
US7098309B2 (en) * 1998-12-23 2006-08-29 Merck & Co., Inc. Recombinant hepatitis B surface antigen
US7172762B1 (en) * 1999-01-29 2007-02-06 Pfizer Inc. Erysipelothrix rhusiopathiae antigens and vaccine compositions
GB9923060D0 (en) 1999-09-29 1999-12-01 Chiron Spa Vaccine
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
KR100374813B1 (ko) * 2000-04-07 2003-03-03 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드, 정제백일해 및비형간염표면항원을 포함한 4가 혼합백신 및 그 제조 방법
SI1296715T2 (sl) 2000-06-29 2016-03-31 Smithkline Beecham Biologicals S.A. Multivalentni sestavek cepiva
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
EP2957300B1 (en) 2001-01-23 2021-07-14 Sanofi Pasteur Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine
AU2007200116A1 (en) * 2001-04-03 2007-02-01 Glaxosmithkline Biologicals S.A. Vaccine composition
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
EP1409013B1 (en) * 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
DK1490100T3 (da) * 2002-03-28 2012-03-12 Brenntag Biosector As Kombinerede DNA/proteinvaccinepræparater
GB0223355D0 (en) * 2002-10-08 2002-11-13 Chiron Spa Vaccine
US8409587B2 (en) 2002-11-01 2013-04-02 Glaxosmithkline Biologicals S.A. Immunogenic composition
PT2172213E (pt) 2003-01-30 2013-06-03 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
RU2238105C1 (ru) * 2003-03-14 2004-10-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантная вакцина для профилактики вирусного гепатита в (варианты)
RU2233672C1 (ru) * 2003-03-31 2004-08-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в и д, столбняка и дифтерии
RU2233673C1 (ru) * 2003-03-31 2004-08-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" Комбинированная вакцина для иммунопрофилактики коклюша, дифтерии, столбняка и вирусного гепатита в и д
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
CA2540896C (en) 2003-10-02 2015-06-02 Chiron Srl Liquid vaccines for multiple meningococcal serogroups
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
WO2005117965A1 (en) 2004-06-04 2005-12-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for preparing immunogenic conjugates
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
WO2006113528A2 (en) 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
EP2201961B1 (en) 2005-06-27 2018-01-24 GlaxoSmithKline Biologicals S.A. Immunogenic composition
GB0517719D0 (en) * 2005-08-31 2005-10-05 Chiron Srl Vaccines containing pili
WO2007026249A2 (en) 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Multiple vaccination including serogroup c meningococcus
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
EP1862176A1 (de) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
EP1862177A1 (de) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
GB0616226D0 (en) * 2006-08-15 2006-09-27 Novartis Ag Processes
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
SI2097102T1 (sl) 2006-09-07 2012-09-28 Glaxosmithkline Biolog Sa Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
GB0617602D0 (en) * 2006-09-07 2006-10-18 Glaxosmithkline Biolog Sa Vaccine
SG178761A1 (en) * 2007-02-07 2012-03-29 Sigma Tau Ind Farmaceuti Recombinant antigens of human cytomegalovirus (hcmv)
PE20090212A1 (es) 2007-05-02 2009-03-30 Glaxosmithkline Biolog Sa Kit de vacuna para la inmunizacion primaria
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
PE20100366A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
IT1398927B1 (it) 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
EP2547357A1 (en) 2010-03-18 2013-01-23 Novartis AG Adjuvanted vaccines for serogroup b meningococcus
FR2966044B1 (fr) * 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
CN103282375B (zh) 2010-12-02 2017-01-11 比奥诺尔免疫有限公司 肽支架设计
EP2661277A2 (en) 2011-01-05 2013-11-13 Bharat Biotech International Limited A combination heptavalent vaccine
CN103347892B (zh) 2011-01-06 2016-11-02 比奥诺尔免疫有限公司 单体和多聚体免疫原性肽
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
CA2835510A1 (en) * 2011-05-11 2012-11-15 Riesbeck Healthcare Sweden Ab Protein f - a novel haemophilus influenzae adhesin with laminin and vitronectin binding properties
US20140234360A1 (en) 2011-09-30 2014-08-21 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Influenza vaccine
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
FR2985663B1 (fr) * 2012-01-17 2015-03-27 Sanofi Pasteur Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium
CA2862560A1 (en) 2012-02-01 2013-08-08 Glaxosmithkline Biologicals S.A. Fermentation process for bordetella species
CN104159603A (zh) * 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
WO2013182661A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
WO2014024026A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
EP2906239A1 (en) 2012-10-12 2015-08-19 GlaxoSmithKline Biologicals SA Non-cross-linked acellular pertussis antigens for use in combination vaccines
BR112015021523A8 (pt) 2013-03-08 2021-06-29 Crucell Holland Bv composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
WO2014164727A1 (en) 2013-03-12 2014-10-09 Wisconsin Alumni Research Foundation A method of treating fungal infection
EP3030260A1 (en) 2013-08-05 2016-06-15 GlaxoSmithKline Biologicals S.A. Combination immunogenic compositions
AR101256A1 (es) 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
TN2018000063A1 (en) * 2015-09-16 2019-07-08 Lg Chemical Ltd Combination vaccine composition for multiple-dosage.
EP3518968B1 (en) 2016-10-03 2022-01-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hiv-1 env fusion peptide immunogens and their use
US11202824B2 (en) 2016-10-31 2021-12-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
EP3600405B1 (en) 2017-03-24 2025-08-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Glycan-masked engineered outer domains of hiv-1 gp120 and their use
MX2020000441A (es) 2017-07-18 2020-08-17 Serum Inst Of India Pvt Ltd Una composicion inmunogenica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparacion de la misma.
WO2019079337A1 (en) 2017-10-16 2019-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE
WO2020043874A1 (en) 2018-08-31 2020-03-05 Glaxosmithkline Biologicals Sa Conjugated haemophilus influenzae vaccine using bordetella outer membrane vesicle
WO2020061564A1 (en) 2018-09-23 2020-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
WO2020086483A1 (en) 2018-10-22 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant gp120 protein with v1-loop deletion
AU2020277403A1 (en) 2019-05-20 2022-01-06 Soligenix, Inc. Compositions and methods of manufacturing trivalent filovirus vaccines
US12210017B2 (en) 2020-01-08 2025-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptides representing epitopes from filoviruses
EP4103587A1 (en) 2020-02-14 2022-12-21 Immunor AS Corona virus vaccine
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
WO2022224966A1 (ja) * 2021-04-20 2022-10-27 Ｋｍバイオロジクス株式会社 ６種混合液状ワクチン組成物
EP4380613A1 (en) 2021-08-03 2024-06-12 The United States of America, as represented by the Secretary, Department of Health and Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
US20250197455A1 (en) 2022-03-27 2025-06-19 TThe United States of America, as represented by the Secretary, Department of Health and Human Servi Base-covered hiv-1 envelope ectodomains and their use
WO2024249626A1 (en) 2023-05-30 2024-12-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 envelope triple tandem trimers and their use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6013718A (ja) * 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
JPS60193925A (ja) * 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
ZA88488B (en) 1987-01-30 1988-10-26 Smith Kline Rit Hepatitis b virus surface antigens and hybrid antigens containing them
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
DE3789866T2 (de) 1987-07-17 1994-09-22 Rhein Biotech Gesellschaft Fuer Neue Biotechnologische Prozesse Und Produkte Mbh, 40595 Duesseldorf DNA-Moleküle, die für FMDH-Kontrollabschnitte und Strukturgene für ein Protein mit FMDH-Aktivität kodieren, sowie deren Anwendung.
JPH085804B2 (ja) * 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
DK0414374T3 (da) 1989-07-25 1998-03-09 Smithkline Beecham Biolog Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
ATE134194T1 (de) 1989-11-06 1996-02-15 Smithkline Beecham Biolog Verfahren
ATE129159T1 (de) 1990-02-12 1995-11-15 Smithkline Beecham Biolog Impfstoff.
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
JPH06503821A (ja) * 1990-12-20 1994-04-28 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） Ｂ型肝炎表面抗原に基づくワクチン
CA2067003A1 (en) 1991-04-29 1992-10-30 Peter J. Kniskern Hbsag escape mutant vaccine
WO1993005811A1 (en) * 1991-09-18 1993-04-01 Amgen Inc. A hepatitis b vaccine formulation incorporating a bile acid salt
AU685443B2 (en) * 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
EP1082965B1 (en) 1995-06-23 2009-06-10 GlaxoSmithKline Biologicals S.A. A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
RU2130778C1 (ru) 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
KR100385711B1 (ko) 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
KR100401423B1 (ko) 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2499046C2 (ru) * 2007-10-30 2013-11-20 Сентро Де Инхеньерия Хенетика И Биотекнолохия Полинуклеотидная последовательность, кодирующая сконструированный белок пертактин, вектор, включающий такую последовательность, и вакцинные композиции, содержащие белок пертактина или вектор
RU2465316C1 (ru) * 2011-10-05 2012-10-27 Общество с ограниченной ответственностью "ГРИТВАК" Штамм бактерий haemophilus influenzae в №326, стабильный продуцент капсульного полисахарида

Also Published As

Publication number Publication date
HUT71791A (en) 1996-02-28
NO944475L (no) 1995-01-18
EP2156845A1 (en) 2010-02-24
EP0642355A1 (en) 1995-03-15
HK1021142A1 (en) 2000-06-02
DE69334297D1 (de) 2009-11-12
KR950701822A (ko) 1995-05-17
IL105770A0 (en) 1993-09-22
CA2136429A1 (en) 1993-12-09
DE122010000015I1 (de) 2010-07-08
CY2614B2 (en) 2012-01-25
WO1993024148A1 (en) 1993-12-09
CZ289294A3 (en) 1995-09-13
DE122010000016I1 (de) 2010-07-08
SG48365A1 (en) 1998-04-17
DK0835663T3 (da) 2010-02-01
AU2007201162A1 (en) 2007-04-19
AU709406C (en) 2004-04-08
FI945483A0 (fi) 1994-11-22
HU9403366D0 (en) 1995-02-28
SK142194A3 (en) 1995-08-09
AP567A (en) 1996-11-25
AP9300530A0 (en) 1993-07-31
EP0835663A2 (en) 1998-04-15
AU2010200249B2 (en) 2012-01-12
CN1085450A (zh) 1994-04-20
AU2010200249A1 (en) 2010-02-11
DK0642355T3 (da) 1998-11-30
PT835663E (pt) 2010-01-04
AU785433B2 (en) 2007-05-31
KR100287083B1 (ko) 2001-04-16
SK280702B6 (sk) 2000-06-12
NZ253065A (en) 1996-10-28
MA22894A1 (fr) 1993-12-31
DE69319728D1 (de) 1998-08-20
EP0642355B1 (en) 1998-07-15
DE69319728T2 (de) 1999-02-04
US6013264A (en) 2000-01-11
EP0835663B1 (en) 2009-09-30
AU1648097A (en) 1997-05-29
RU2160120C2 (ru) 2000-12-10
NO309675B1 (no) 2001-03-12
CZ283910B6 (cs) 1998-07-15
ATE168271T1 (de) 1998-08-15
JPH07508267A (ja) 1995-09-14
LU91658I2 (fr) 2010-05-03
CN1313152C (zh) 2007-05-02
JP3626996B2 (ja) 2005-03-09
NO944475D0 (no) 1994-11-22
MY110665A (en) 1999-01-30
AU5062902A (en) 2002-08-08
CA2136429C (en) 2001-12-11
AU4315693A (en) 1993-12-30
HK1011290A1 (en) 1999-07-09
MX9302982A (es) 1993-12-01
IL105770A (en) 1998-08-16
EP2289548A2 (en) 2011-03-02
LU91659I2 (fr) 2010-05-03
EP0835663A3 (en) 1999-03-03
RU94046145A (ru) 1997-03-27
HU220236B (hu) 2001-11-28
CN1136918C (zh) 2004-02-04
ES2118963T3 (es) 1998-10-01
ES2334181T3 (es) 2010-03-05
FI945483L (fi) 1995-01-20
EP2289548A3 (en) 2012-08-08
AU709406B2 (en) 1999-08-26
FI945483A7 (fi) 1995-01-20
CN1623602A (zh) 2005-06-08
ATE444079T1 (de) 2009-10-15
SI9300271A (en) 1993-12-31

Similar Documents

Publication Publication Date Title
UA40596C2 (uk) Композиція вакцини та спосіб її одержання
ES2092306T3 (es) Adyuvante para vacunas.
ZA956412B (en) Mutant enterotoxin effective as a non-toxic oral adjuvant
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
UA40597C2 (uk) Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
IL111134A (en) Immunological tolerance-inducing composition comprising a mucosa-binding molecule linked to a specific self-antigen/tolerogen
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
EP0362279A4 (en) SAPONINE TOOLS.
PL304419A1 (en) Urease based vaccine against heliobacter infections
NL300402I1 (en) Method and manufacture of an acellular vaccine comprising Bordetella pertussis antigens
NZ314585A (en) Method of treating H. Pylori associated gastroduodenal disease
DE3473825D1 (en) Method of preparing adjuvanted live vaccines and adjuvanted live vaccines thus obtained
DE69333448D1 (en) P53 impfstoff
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
ES458197A1 (es) Un procedimiento para la preparacion de nuevos peptidoglica-nos.
CA2078605A1 (en) Chicken anaemia agent vaccine
DE3269188D1 (en) Vaccine for hepatitis
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
IL100765A0 (en) Vaccine composition against influenza,with synergic effects containing influenza virus core as an additive
EP0563288A4 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
KR920003992A (ko) 백일해, 디프테리아, 파상풍 및 b형 간염의 동시예방을 위한 혼합백신
RU93005000A (ru) Композиция вакцин, способ ее получения, способ исключения иммунной реакции